LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

Accueil・Liste d'Actions・Editas Medicine Inc

Editas Medicine Inc

Ouvert

SecteurSoins de santé

2.78 -2.46

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.61

Max

2.9

Chiffres clés
By Trading Economics
Revenu	-19M -25M
Ventes	-22M 2.8M
BPA	-0.26
Marge bénéficiaire	-882.444
Employés	87
EBITDA	-19M -25M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+125.89% upside

Dividendes
By Dow Jones
Prochains Résultats	10 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	219M 513M
Ouverture précédente	5.24
Clôture précédente	2.78

Sentiment de l'Actualité

By Acuity

58%

42%

265 / 344 Classement par Healthcare

Editas Medicine Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 juin 2026, 20:30 UTC

Résultats

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 juin 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 juin 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 juin 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 juin 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 juin 2026, 23:01 UTC

Acquisitions, Fusions, Rachats

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 juin 2026, 23:01 UTC

Acquisitions, Fusions, Rachats

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 juin 2026, 23:00 UTC

Acquisitions, Fusions, Rachats

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 juin 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 juin 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 juin 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 juin 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 juin 2026, 21:00 UTC

Résultats

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2 juin 2026, 20:46 UTC

Résultats

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 juin 2026, 20:38 UTC

Résultats

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 juin 2026, 20:21 UTC

Résultats

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 juin 2026, 20:12 UTC

Résultats

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks 3Q Product Rev $594M

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks 3Q Loss $177M >PANW

Comparaison

Variation de prix

Editas Medicine Inc prévision

Objectif de Prix

By TipRanks

125.89% hausse

Prévisions sur 12 Mois

Moyen 6.37 USD 125.89%

Haut 15 USD

Bas 4 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

Achat

Maintien

Vente

Basé sur 11 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

265 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.